Aggiornamento
Le spondiloartropatie giovanili
Juvenile spondyloarthropathies
Ballaben A, Vrinceanu A, Pastore S, Taddio A.
Novembre 2025 - pagg. 563 -567 | DOI: 10.53126/MEB44563
Abstract
Juvenile spondyloarthropathies (JSpA) are a heterogeneous group of chronic inflammatory diseases, including enthesitis-related arthritis (ERA), juvenile psoriatic arthritis (JPsA) and undifferentiated arthritis. Many clinical features overlap with other juvenile idiopathic arthritis, whereas an involvement of enthesis and sacroiliac joints is typical. Therapy is based upon the use of DMARDs and anti-TNF alpha drugs. An optimal diagnostic and therapeutic approach is often challenging, as JSpA have a poorer prognosis and quality of life than other arthritis.
Riassunto
Le spondiloartropatie giovanili (JSpA) sono un gruppo eterogeneo di malattie infiammatorie croniche, che comprendono l’artrite correlata ad entesite (ERA), l’artrite psoriasica giovanile (JPsA) e l’artrite indifferenziata. Spesso possono presentare elementi clinici sovrapponibili ad altre artriti idiopatiche giovanili, mentre si distinguono per l’interessamento delle entesi e delle articolazioni sacroiliache. La terapia si basa principalmente sull’utilizzo di DMARDs e anti TNF-alfa. Un percorso diagnostico-terapeutico ottimale non è facile da garantire, in quanto patologie gravate da una peggior prognosi e qualità di vita rispetto ad altre artriti.
Classificazione MeSH
Contenuto riservato
Per leggere l'articolo completo è necessario effettuare il login.
Non sei ancora registrato? Registrati
Bibliografia
1. Srinivasalu H, Sikora KA, Colbert RA. Recent Updates in Juvenile Spondyloarthritis. Rheum Dis Clin North Am 2021;47(4):565-83. doi: 10.1016/j.rdc.2021.07.001.
2. Consolaro A, Giancane G, Alongi A, et al.; Paediatric Rheumatology International Trials Organisation. Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. Lancet Child Adolesc Health 2019;3(4):255-63. doi: 10.1016/S2352-4642(19)30027-6.
3. Rebollo-Giménez AI, Rosina S, Natoli V, et al.; Paediatric Rheumatology International Trials Organisation (PRINTO). Clinical features, treatment and outcomes of Italian children with enthesitis-related arthritis and juvenile psoriatic arthritis: a cross-sectional cohort study. Clin Exp Rheumatol 2024;42 (3):757-763. doi: 10.55563/clinexprheumatol/7xby7y.
4. Weiss PF, Fuhlbrigge RC, von Scheven E, Lovell DJ, Colbert RA, Brunner HI; PRCSG Advisory Council and the CARRA Executive Committee. Children With Enthesitis-Related Arthritis and Possible Benefits From Treatments for Adults With Spondyloarthritis. Arthritis Care Res (Hoboken) 2022;74(7): 1058-64. doi: 10.1002/acr.24529.
5. Naveen R, Guleria S, Aggarwal A. Recent updates in enthesitis-related arthritis. Rheumatol Int 2023;43(3):409-20. doi: 10.1007/ s00296-023-05274-w.
6. Gaggiano C, Avramovič MZ, Vitale A, et al. Systemic auto-inflammatory manifestations in patients with spondyloarthritis. Joint Bone Spine 2024;91(6):105772. doi: 10.1016/j.jbspin.2024.105772.
7. Weiss PF, Chauvin NA, Klink AJ, et al. Detection of enthesitis in children with enthesitis-related arthritis: dolorimetry compared to ultrasonography. Arthritis Rheumatol 2014; 66(1):218-27. doi: 10.1002/art.38197.
8. Herregods N, Maksymowych WP, Jans L, et al. Atlas of MRI findings of sacroiliitis in pediatric sacroiliac joints to accompany the updated preliminary OMERACT pediatric JAMRIS (Juvenile Idiopathic Arthritis MRI Score) scoring system: Part I: Active lesions. Semin Arthritis Rheum 2021;51(5):1089-98. doi: 10.1016/j.semarthrit.2021.07.003.
9. Herregods N, Maksymowych WP, Jans L, et al. Atlas of MRI findings of sacroiliitis in pediatric sacroiliac joints to accompany the updated preliminary OMERACT pediatric JAMRIS (Juvenile Idiopathic Arthritis MRI Score) scoring system: Part II: Structural damage lesions. Semin Arthritis Rheum 2021;51 (5):1099-107. doi: 10.1016/j.semarthrit.2021.07.009.
10. Tay SH, Yeo JG, Leong JY, Albani S, Arkachaisri T. Juvenile Spondyloarthritis: What More Do We Know About HLA-B27, Enthesitis, and New Bone Formation? Front Med (Lausanne) 2021;8:666772. doi: 10.3389/fmed.2021.666772.
11. Zisman D, Gladman DD, Stoll ML, et al.; CARRA Legacy Registry Investigators. The Juvenile Psoriatic Arthritis Cohort in the CARRA Registry: Clinical Characteristics, Classification, and Outcomes. J Rheumatol 2017;44(3):342-51. doi: 10.3899/jrheum. 160717.
12. Marino A, Weiss PF, Brandon TG, Lerman MA. Juvenile Spondyloarthritis: focus on uveitis. Pediatr Rheumatol Online J 2020;18(1):70. doi: 10.1186/s12969-020-00463-4.
13. Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Rheumatol 2019;71(6):846-63. doi: 10.1002/art.40884.
14. Brunner HI, Foeldvari I, Alexeeva E, et al.; Paediatric Rheumatology INternational Trials Organization (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG). Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Ann Rheum Dis 2023;82(1):154-60. doi: 10.1136/ ard-2022-222849.
Corrispondenza: andreaballaben@gmail.com